<DOC>
	<DOC>NCT02567695</DOC>
	<brief_summary>The purpose of this study is to evaluate the relative bioavailability of a single 300 mg dose of GBT440 administered as a high strength (1 × 300 mg) capsule versus a low strength (3 × 100 mg) capsule formulation in healthy fasted subjects.</brief_summary>
	<brief_title>A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Subject is a female of nonchildbearing potential or male, who is healthy, nonsmoking, and 18 to 60 years old, inclusive, at screening Male subjects agree to use contraception Willing and able to give written informed consent Evidence or history of clinically significant metabolic, allergic, dermatological, hepatic, renal,hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder History of hypersensitivity or allergy to drugs, foods, or other substances History or presence of abnormal electrocardiogram or hypertension History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 1 year of screening Participated in another clinical trial of an investigational drug within 30 days (or 5 halflives of the investigational drug, whichever is longer) prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>